The American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guidelines acknowledge that “CSII is a less commonly used and more costly alternative” to basal-bolus therapy in patients with T2DM. The Opt2mise was a robust study intended to clarify the role of CSII in patients with T2DM.
view more